Literature DB >> 22183878

Suppression of interferon-α signaling by hepatitis E virus.

Chen Dong1, Mohammad Zafrullah, Tonya Mixson-Hayden, Xing Dai, Jiuhong Liang, Jihong Meng, Saleem Kamili.   

Abstract

UNLABELLED: The interferon (IFN) system is integral to the host response against viruses, and many viruses have developed strategies to overcome its antiviral effects. The effects of hepatitis E virus (HEV), the causative agent of hepatitis E, on IFN signaling have not been investigated primarily because of the nonavailability of an efficient in vitro culture system or small animal models of infection. We report here the generation of A549 cell lines persistently infected with genotype 3 HEV, designated as HEV-A549 cells and the effects HEV has on IFN-α-mediated Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling. Treatment of HEV-A549 cells with 250, 500, and 1000 U/mL of IFN-α for 72 hours showed a dose-dependent reduction in HEV RNA levels by 10%, 20%, and 50%, respectively. IFN-α-stimulated genes coding for the antiviral proteins dsRNA-activated protein kinase (PKR) and 2',5'-oligoadenylate synthetase (2',5'-OAS) were down-regulated in IFN-α-treated HEV-A549 cells. HEV infection also prevented IFN-α-induced phosphorylation of STAT1. Regulation of STAT1 by HEV was specific, as phosphorylation of STAT2, tyrosine kinase (Tyk) 2, and Jak1 by IFN-α was unaltered. Additionally, STAT1 levels were markedly increased in HEV-A549 cells compared with naive A549 cells. Furthermore, binding of HEV open reading frame (ORF)3 protein to STAT1 in HEV-A549 cells was observed. HEV ORF3 protein alone inhibited IFN-α-induced phosphorylation of STAT1 and down-regulated the IFN-α-stimulated genes encoding PKR, 2',5'-OAS, and myxovirus resistance A.
CONCLUSION: HEV inhibits IFN-α signaling through the regulation of STAT1 phosphorylation in A549 cells. These findings have implications for the development of new strategies against hepatitis E.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22183878     DOI: 10.1002/hep.25530

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Enhancement of interferon induction by ORF3 product of hepatitis E virus.

Authors:  Yuchen Nan; Zexu Ma; Rong Wang; Ying Yu; Harilakshmi Kannan; Brenda Fredericksen; Yan-Jin Zhang
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

2.  The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection.

Authors:  Qiu-Yan Chang; Fu-Cheng Guo; Xue-Rui Li; Jian-Hua Zhou; Xuepeng Cai; Qiuwei Pan; Xiao-Xia Ma
Journal:  Vet Res Commun       Date:  2018-08-09       Impact factor: 2.459

3.  Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.

Authors:  Xianfang Wu; Viet Loan Dao Thi; Peng Liu; Constantin N Takacs; Kuanhui Xiang; Linda Andrus; Jérôme Gouttenoire; Darius Moradpour; Charles M Rice
Journal:  Gastroenterology       Date:  2017-12-24       Impact factor: 22.682

Review 4.  Chronic hepatitis e virus infection and treatment.

Authors:  Nassim Kamar; Jacques Izopet; Harry R Dalton
Journal:  J Clin Exp Hepatol       Date:  2013-05-25

Review 5.  Stem Cell-Derived Culture Models of Hepatitis E Virus Infection.

Authors:  Viet Loan Dao Thi; Xianfang Wu; Charles M Rice
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 6.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Harry R Dalton; Florence Abravanel; Jacques Izopet
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

7.  Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.

Authors:  Daniel Todt; Catherine François; Patrick Behrendt; Michael Engelmann; Leonard Knegendorf; Gabrielle Vieyres; Heiner Wedemeyer; Rune Hartmann; Thomas Pietschmann; Gilles Duverlie; Eike Steinmann
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.

Authors:  Harini Sooryanarain; Adam J Rogers; Dianjun Cao; Mary Etna R Haac; Yogesh A Karpe; Xiang-Jin Meng
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

9.  3Cpro of foot-and-mouth disease virus antagonizes the interferon signaling pathway by blocking STAT1/STAT2 nuclear translocation.

Authors:  Yijun Du; Jingshan Bi; Jiyu Liu; Xing Liu; Xiangju Wu; Ping Jiang; Dongwan Yoo; Yongguang Zhang; Jiaqiang Wu; Renzhong Wan; Xiaomin Zhao; Lihui Guo; Wenbo Sun; Xiaoyan Cong; Lei Chen; Jinbao Wang
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 10.  Hepatitis E virus infection: Epidemiology and treatment implications.

Authors:  Ga Young Lee; Kittiyod Poovorawan; Duangnapa Intharasongkroh; Pattaratida Sa-Nguanmoo; Sompong Vongpunsawad; Chintana Chirathaworn; Yong Poovorawan
Journal:  World J Virol       Date:  2015-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.